Scott J. Diede

6.5k total citations · 2 hit papers
67 papers, 4.3k citations indexed

About

Scott J. Diede is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Scott J. Diede has authored 67 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 37 papers in Molecular Biology and 9 papers in Immunology. Recurrent topics in Scott J. Diede's work include Cancer Immunotherapy and Biomarkers (36 papers), CAR-T cell therapy research (35 papers) and Melanoma and MAPK Pathways (20 papers). Scott J. Diede is often cited by papers focused on Cancer Immunotherapy and Biomarkers (36 papers), CAR-T cell therapy research (35 papers) and Melanoma and MAPK Pathways (20 papers). Scott J. Diede collaborates with scholars based in United States, Australia and France. Scott J. Diede's co-authors include Daniel E. Gottschling, Georgina V. Long, Reinhard Dummer, Thomas F. Gajewski, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, James R. Anderson and Olivier Michielin and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Scott J. Diede

61 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

2017 1.1k citations Antoni Ribas, Reinhard Dummer et al. Cell profile →
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

2019 703 citations Georgina V. Long, Reinhard Dummer et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott J. Diede United States	24	2.5k	1.9k	1.3k	710	487	67	4.3k
Yoko Oei United States	12	1.1k 0.4×	1.4k 0.7×	1.9k 1.5×	170 0.2×	332 0.7×	17	3.6k
Monica Gostissa United States	26	2.0k 0.8×	4.3k 2.3×	994 0.8×	384 0.5×	316 0.6×	45	5.4k
Hao Zhao United States	18	1.6k 0.6×	1.0k 0.6×	1.3k 1.0×	236 0.3×	140 0.3×	33	3.1k
Ralph Meuwissen Netherlands	19	1.4k 0.6×	2.6k 1.4×	348 0.3×	428 0.6×	112 0.2×	25	4.1k
Michael P. Cooke United States	21	547 0.2×	1.4k 0.8×	2.1k 1.6×	327 0.5×	177 0.4×	69	3.9k
Dirce Maria Carraro Brazil	33	929 0.4×	1.8k 1.0×	181 0.1×	585 0.8×	166 0.3×	188	3.4k
Ankur Chakravarthy Canada	18	1.1k 0.4×	2.2k 1.2×	905 0.7×	277 0.4×	64 0.1×	29	3.5k
Charles De Smet Belgium	30	1.1k 0.5×	3.4k 1.9×	3.0k 2.3×	498 0.7×	135 0.3×	55	5.1k
Issay Kitabayashi Japan	41	1.1k 0.5×	4.4k 2.4×	1.2k 0.9×	557 0.8×	132 0.3×	121	6.1k
Liqing Jin Canada	20	1.3k 0.5×	2.2k 1.2×	860 0.7×	290 0.4×	95 0.2×	41	3.9k

Countries citing papers authored by Scott J. Diede

Since Specialization

Citations

This map shows the geographic impact of Scott J. Diede's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott J. Diede with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott J. Diede more than expected).

Fields of papers citing papers by Scott J. Diede

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott J. Diede. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott J. Diede. The network helps show where Scott J. Diede may publish in the future.

Co-authorship network of co-authors of Scott J. Diede

This figure shows the co-authorship network connecting the top 25 collaborators of Scott J. Diede. A scholar is included among the top collaborators of Scott J. Diede based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott J. Diede. Scott J. Diede is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arance, Ana, Miguel‐Ángel Berciano‐Guerrero, Jun Guo, et al.. (2025). Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma. Annals of Oncology. 36(12). 1535–1546.

Chen, Alice P., Geraldine O’Sullivan Coyne, Pamela L. Wolters, et al.. (2025). Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. The Lancet. 405(10496). 2217–2230. 1 indexed citations

Dummer, Reinhard, Jean‐Jacques Grob, Caroline Robert, et al.. (2024). Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.. Journal of Clinical Oncology. 42(16_suppl). 9506–9506. 2 indexed citations

Tan, Xiang‐Lin, Huilin Tang, Jiali Han, et al.. (2022). Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases. Frontiers in Oncology. 12. 1025664–1025664. 4 indexed citations

Hamid, Omid, Caroline Robert, Adil Daud, et al.. (2021). Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer. 157. 391–402. 19 indexed citations

Ferrucci, Pier Francesco, Anna Maria Di Giacomo, Michele Del Vecchio, et al.. (2020). KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. Journal for ImmunoTherapy of Cancer. 8(2). e001806–e001806. 111 indexed citations

Arance, Ana, Steven O’Day, Luis de la Cruz‐Merino, et al.. (2020). LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004. Annals of Oncology. 31. S1173–S1173. 19 indexed citations

Joseph, Richard W., Frank Xiaoqing Liu, Alicia C. Shillington, et al.. (2020). Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings. Quality of Life Research. 29(10). 2651–2660. 18 indexed citations

Geoerger, Birgit, Hyoung Jin Kang, Michal Yalon-Oren, et al.. (2019). Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. The Lancet Oncology. 21(1). 121–133. 208 indexed citations

10.

Long, Georgina V., Reinhard Dummer, Omid Hamid, et al.. (2019). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. The Lancet Oncology. 20(8). 1083–1097. 703 indexed citations breakdown →

11.

Si, Lu, Xiaoshi Zhang, Yongqian Shu, et al.. (2019). A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). Translational Oncology. 12(6). 828–835. 99 indexed citations

12.

Pinto, Navin, Steven G. DuBois, Araz Marachelian, et al.. (2018). Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatric Blood & Cancer. 65(7). e27023–e27023. 27 indexed citations

13.

Robert, Caroline, Antoni Ribas, Omid Hamid, et al.. (2017). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 36(17). 1668–1674. 336 indexed citations

14.

Watanabe, Takaaki, Michael Marotta, Ryusuke Suzuki, et al.. (2017). Impediment of Replication Forks by Long Non-coding RNA Provokes Chromosomal Rearrangements by Error-Prone Restart. Cell Reports. 21(8). 2223–2235. 13 indexed citations

15.

Marotta, Michael, Xiongfong Chen, Takaaki Watanabe, et al.. (2013). Homology-mediated end-capping as a primary step of sister chromatid fusion in the breakage-fusion-bridge cycles. Nucleic Acids Research. 41(21). 9732–9740. 16 indexed citations

16.

Yao, Zizhen, et al.. (2012). Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas. Epigenetics. 7(4). 400–408. 52 indexed citations

17.

Guenthoer, Jamie, Scott J. Diede, Hisashi Tanaka, et al.. (2011). Assessment of palindromes as platforms for DNA amplification in breast cancer. Genome Research. 22(2). 232–245. 28 indexed citations

18.

Page, Barbara D., Scott J. Diede, Jennifer R. Tenlen, & Edwin L. Ferguson. (2007). EEL-1, a Hect E3 ubiquitin ligase, controls asymmetry and persistence of the SKN-1 transcription factor in the early C. elegans embryo. Development. 134(12). 2303–2314. 23 indexed citations

19.

Diede, Scott J. & Daniel E. Gottschling. (2001). Exonuclease activity is required for sequence addition and Cdc13p loading at a de novo telomere. Current Biology. 11(17). 1336–1340. 121 indexed citations

20.

Diede, Scott J. & Daniel E. Gottschling. (1999). Telomerase-Mediated Telomere Addition In Vivo Requires DNA Primase and DNA Polymerases α and δ. Cell. 99(7). 723–733. 319 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact